Science and Technology Production
Article
Authorship
Bruni, Sofia
;
MERCOGLIANO, MARIA FLORENCIA
;
Mauro, Florencia Luciana
;
Cordo Russo, Rosalia Ines
;
SCHILLACI, ROXANA
Date
2023
Publishing House and Editing Place
Frontiers Media S.A.
Magazine
Frontiers in Oncology,
vol. 13
(pp. 1-25)
Frontiers Media S.A.
Summary
Information provided by the agent in
SIGEVA
Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving posi...
Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion.
Show more
Show less
Key Words
EXTRACELLULAR MATRIXTUMOR INFILTRATING LYMPHOCYTES (TILS)PHYSICAL BARRIERTUMOR-ASSOCIATED VASCULATUREMYELOID CELLSTUMOR-ASSOCIATED MACROPHAGE (TAMS)IMMUNE EXCLUSIONTUMOR MICROENVIRONMENT
Download or request the full text